Safety	safety	O	O
of	of	O	O
capecitabine	capecitabine	S_chemicals	O
:	:	O	O
a	a	O	O
review	review	O	O
.	.	O	O

IMPORTANCE	importance	O	O
OF	of	O	O
THE	the	O	O
FIELD	field	O	O
:	:	O	O
Fluoropyrimidines	fluoropyrimidines	O	O
,	,	O	O
in	in	O	O
particular	particular	O	O
5-fluorouracil	5-fluorouracil	O	O
(	(	O	O
5-FU	5-fu	O	O
)	)	O	O
,	,	O	O
have	have	O	O
been	been	O	O
the	the	O	O
mainstay	mainstay	O	O
of	of	O	O
treatment	treatment	O	O
for	for	O	O
several	several	O	O
solid	solid	O	O
tumors	tumors	O	S_disease
,	,	O	O
including	including	O	O
colorectal	colorectal	O	O
,	,	O	O
breast	breast	O	O
and	and	O	O
head	head	O	B_disease
and	and	O	I_disease
neck	neck	O	B_disease
cancers	cancers	O	S_disease
,	,	O	O
for	for	O	O
>	>	O	O
40	40	O	O
years	years	O	O
.	.	O	O

AREAS	areas	O	O
COVERED	covered	O	O
IN	in	O	O
THIS	this	O	O
REVIEW	review	O	O
:	:	O	O
This	this	O	O
article	article	O	O
reviews	reviews	O	O
the	the	O	O
pharmacology	pharmacology	O	O
and	and	O	O
efficacy	efficacy	O	O
of	of	O	O
capecitabine	capecitabine	S_chemicals	O
with	with	O	O
a	a	O	O
special	special	O	O
emphasis	emphasis	O	O
on	on	O	O
its	its	O	O
safety	safety	O	O
.	.	O	O

WHAT	what	O	O
THE	the	O	O
READER	reader	O	O
WILL	will	O	O
GAIN	gain	O	O
:	:	O	O
The	the	O	O
reader	reader	O	O
will	will	O	O
gain	gain	O	O
better	better	O	O
insight	insight	O	O
into	into	O	O
the	the	O	O
safety	safety	O	O
of	of	O	O
capecitabine	capecitabine	S_chemicals	O
in	in	O	O
special	special	O	O
populations	populations	O	O
such	such	O	O
as	as	O	O
patients	patients	O	O
with	with	O	O
advanced	advanced	O	O
age	age	O	O
,	,	O	O
renal	renal	O	O
and	and	O	O
kidney	kidney	O	B_disease
disease	disease	O	S_disease
.	.	O	O

We	we	O	O
also	also	O	O
explore	explore	O	O
different	different	O	O
dosing	dosing	O	O
and	and	O	O
schedules	schedules	O	O
of	of	O	O
capecitabine	capecitabine	S_chemicals	O
administration	administration	O	O
.	.	O	O

TAKE	take	O	O
HOME	home	O	O
MESSAGE	message	O	O
:	:	O	O
Capecitabine	capecitabine	S_chemicals	O
is	is	O	O
an	an	O	O
oral	oral	O	O
prodrug	prodrug	S_chemicals	O
of	of	O	O
5-FU	5-fu	O	O
and	and	O	O
was	was	O	O
developed	developed	O	O
to	to	O	O
fulfill	fulfill	O	O
the	the	O	O
need	need	O	O
for	for	O	O
a	a	O	O
more	more	O	O
convenient	convenient	O	O
therapy	therapy	O	O
and	and	O	O
provide	provide	O	O
an	an	O	O
improved	improved	O	O
safety/efficacy	safety/efficacy	O	O
profile	profile	O	O
.	.	O	O

It	it	O	O
has	has	O	O
shown	shown	O	O
promising	promising	O	O
results	results	O	O
alone	alone	O	O
or	or	O	O
in	in	O	O
combination	combination	O	O
with	with	O	O
other	other	O	O
chemotherapeutic	chemotherapeutic	O	O
agents	agents	O	O
in	in	O	O
colorectal	colorectal	O	O
,	,	O	O
breast	breast	O	O
,	,	O	O
pancreaticobiliary	pancreaticobiliary	O	S_disease
,	,	O	O
gastric	gastric	O	O
,	,	O	O
renal	renal	O	B_disease
cell	cell	O	I_disease
and	and	O	O
head	head	O	B_disease
and	and	O	I_disease
neck	neck	O	B_disease
cancers	cancers	O	S_disease
.	.	O	O

The	the	O	O
most	most	O	O
commonly	commonly	O	O
reported	reported	O	O
toxic	toxic	O	O
effects	effects	O	O
of	of	O	O
capecitabine	capecitabine	S_chemicals	O
are	are	O	O
diarrhea	diarrhea	O	S_disease
,	,	O	O
nausea	nausea	O	O
,	,	O	O
vomiting	vomiting	O	S_disease
,	,	O	O
stomatitis	stomatitis	O	S_disease
and	and	O	O
hand-foot	hand-foot	O	B_disease
syndrome	syndrome	O	S_disease
.	.	O	O

Capecitabine	capecitabine	S_chemicals	O
has	has	O	O
a	a	O	O
well-established	well-established	O	O
safety	safety	O	O
profile	profile	O	O
and	and	O	O
can	can	O	O
be	be	O	O
given	given	O	O
safely	safely	O	O
to	to	O	O
patients	patients	O	O
with	with	O	O
advanced	advanced	O	O
age	age	O	O
,	,	O	O
hepatic	hepatic	O	O
and	and	O	O
renal	renal	O	O
dysfunctions	dysfunctions	O	O
.	.	O	O

